OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
More than one route to render tumors resistant to cGAS/STING activation	613
Subscription and Copyright Information	397
Subscription and Copyright Information	236
Subscription and Copyright Information	178
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders	165
Subscription and Copyright Information	153
The N terminus-only function of adhesion GPCRs: emerging concepts	151
IRAK4: potential therapeutic target for airway disease exacerbations	146
Anticancer drugs: How to select small molecule combinations?	135
Subscription and Copyright Information	132
Subscription and Copyright Information	129
Advisory Board and Contents	128
Subscription and Copyright Information	124
Epitope landscape in autoimmune neurological disease and beyond	112
Advisory Board and Contents	104
Atogepant (Qulipta®) for migraine prevention	100
Promoting spliceosome assembly for therapeutic intent	97
Advisory Board and Contents	88
Advisory Board and Contents	86
Paving the way for designing drugs targeting TMEM16A	85
Subscription and Copyright Information	84
Advisory Board and Contents	76
Subscription and Copyright Information	76
Subscription and Copyright Information	75
Subscription and Copyright Information	72

Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs	70
Subscription and Copyright Information	69
Advisory Board and Contents	63
Lenacapavir (Sunlenca®) for the treatment of HIV-1	62
The consequences of particle uptake on immune cells	60
Subscription and Copyright Information	58
Boosting CAR-T cell therapy through vaccine synergy	58
Key metrics to expanding the pipeline of successful antibody–drug conjugates	57
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	57
Futibatinib (Lytgobi) for cholangiocarcinoma	57
Obesity pharmacotherapy: incretin action in the central nervous system	56
Channeling Force in the Brain: Mechanosensitive Ion Channels Choreograph Mechanics and Malignancies	54
Targeting of Potassium Channels in Cardiac Arrhythmias	54
Harnessing associative learning paradigms to optimize drug treatment	54
Shearing of surface mucin saps tumor cell strength	53
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	53
Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology	51
Tackling chronic kidney disease in diabetic patients with finerenone	50
A novel anticancer pharmacological agent targeting mitochondrial complex I	50
Biologics and cardiac disease: challenges and opportunities	49
Translational adaptation in breast cancer metastasis and emerging therapeutic opportunities	48
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research	47
Structural asymmetry in FGF23 signaling	47
RH5 antigenic landscape shapes vaccine and antibody development	47
Leveraging macrophage metabolism for anticancer therapy: opportunities and pitfalls	47
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	46
Spare the pain for your gut Treg cells!	46
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	46
Discovery of De Novo Macrocyclic Peptides by Messenger RNA Display	45
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	45
Muscarinic receptors: from clinic to bench to clinic	44
Potential therapeutic targets for trauma management	44
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	43
Subscription and Copyright Information	43
Chemokine receptor CCR1: new target for asthma therapy	42
Directions to overcome therapy resistance in cancer	41
Unifying mechanism behind the onset of acquired epilepsy	41
Current clinical translation of microbiome medicines	41
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	39
Subscription and Copyright Information	39
Targeting natural killer cells to enhance vaccine responses	39
Nanotherapeutic-directed approaches to analgesia	39
Artificial protein coronas: directing nanoparticles to targets	38
Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges	38
Targeting sensory neuron GPCRs for peripheral neuropathic pain	38
Tackling therapy resistance in cancer	38
Deep mutational scanning for therapeutic antibody engineering	37
Peptides as a therapeutic strategy against Klebsiella pneumoniae	37
Acid-sensing ion channels as potential therapeutic targets	37
Visceral obesity and HFpEF: targets and therapeutic opportunities	36

Emerging autism and Fragile X syndrome treatments	33
Casimersen for the treatment of Duchenne muscular dystrophy	32
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	32
Proteomic approaches advancing targeted protein degradation	32
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	31
Targeting complement in neurodegeneration: challenges, risks, and strategies	31
CRISPR-based therapeutics: current challenges and future applications	31
ER stress in obesity pathogenesis and management	31
Biomarkers and targeted therapy for cancer stem cells	31
Metastatic colorectal cancer: mechanisms and emerging therapeutics	31
Compstatins: the dawn of clinical C3-targeted complement inhibition	30
Therapeutic inhibition of ferroptosis in neurodegenerative disease	29
Emerging targets in lipid metabolism for cancer therapy	29
Direct in vivo CAR T cell engineering	29
Neutrophil extracellular traps in wound healing	27
High-power screening (HPS) empowered by DNA-encoded libraries	27
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	26
Targeting extranuclear histones to alleviate acute and chronic inflammation	26
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	25
Pain Signaling by GPCRs and RTKs	25
HSV-1 as a gene delivery platform for cancer gene therapy	24
Advisory Board and Contents	24
Ribosome-directed cancer therapies: the tip of the iceberg?	23
Poison exons: tuning RNA splicing for targeted gene regulation	23
GABA transport goes structural	23
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	23
A pharmacological strategy to recapitulate exercise-induced antitumoral immunity	23
GABAA receptors as targets for treating affective and cognitive symptoms of depression	22
Advisory Board and Contents	22
Cancer drug repurposing in autism spectrum disorder	22
Developing novel antifungals: lessons from G protein-coupled receptors	22
A deep dive into degrader-induced protein-protein interfaces	22
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	21
Challenges and opportunities associated with rare-variant pharmacogenomics	21
Advisory Board and Contents	21
Advancing targeted protein degradation modalities	21
Subscription and Copyright Information	21
Biomaterials, biological molecules, and polymers in developing vaccines	21
Advances in the structural understanding of opioid allostery	21
Hedgehog signalling in allograft vasculopathy: a new therapeutic target?	20
Subscription and Copyright Information	20
Defeating MYC with drug combinations or dual-targeting drugs	20
Advisory Board and Contents	20
Subscription and Copyright Information	19
Advisory Board and Contents	19
Supramolecular nanomedicines through rational design of self-assembling prodrugs	18
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	18
Advances in GPCR-targeted drug development in dermatology	18
Circadian biology to advance therapeutics for mood disorders	18
Advisory Board and Contents	17
Advisory Board and Contents	17
Subscription and Copyright Information	17
Subscription and Copyright Information	17
Subscription and Copyright Information	17
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules	17
Model-informed precision dosing in inflammatory bowel diseases	17
Reprogramming RNA processing: an emerging therapeutic landscape	17
Advisory Board and Contents	17
Advisory Board and Contents	17
The 2024 New York City Integrative Structural Biology Symposium	17